BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fyfe MC. Non-systemic Intestine-Targeted Drugs. Prog Med Chem 2016;55:1-44. [PMID: 26852933 DOI: 10.1016/bs.pmch.2015.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Slifer ZM, Krishnan BR, Madan J, Blikslager AT. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol 2021;320:G983-9. [PMID: 33881350 DOI: 10.1152/ajpgi.00386.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Beattie DT, Pulido-Rios MT, Shen F, Ho M, Situ E, Tsuruda PR, Brassil P, Kleinschek M, Hegde S. Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy. J Inflamm (Lond) 2017;14:28. [PMID: 29225517 DOI: 10.1186/s12950-017-0175-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
3 Nakhi A, Wong HL, Weldy M, Khoruts A, Sadowsky MJ, Dosa PI. Structural modifications that increase gut restriction of bile acid derivatives. RSC Med Chem 2021;12:394-405. [PMID: 34046622 DOI: 10.1039/d0md00425a] [Reference Citation Analysis]
4 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Ehrich M, Chauhan J, Bassaganya-Riera J. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. Drug Chem Toxicol 2019;:1-6. [PMID: 31650868 DOI: 10.1080/01480545.2019.1679828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]